Index of artpub/2023/303456/

Blauvelt, Andrew
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis : 52-week results of two randomized double-blinded placebo-controlled phase III trials
2023
https://ddd.uab.cat/record/303456